Intuitive Surgical, Inc. (ISRG) has been one of the most successful medical-technology growth stories of the past two decades, dominating robotic-assisted surgery through its da Vinci and Ion platforms. After peaking near $604 in early 2026, however, the stock has pulled back sharply, leaving investors asking whether the shares can reclaim the psychologically significant $500 price target.
The question is not arbitrary. At roughly $369, $500 represents meaningful upside, and the figure appears repeatedly across the analyst community. Oppenheimer upgraded the stock to Outperform in August 2026 with a $500 target, while Citi, UBS, and Baird hold similar objectives. That makes $500 a genuine focal point of current market discussion rather than a fabricated milestone.
Intuitive Surgical is a stock, not an exchange-traded fund (ETF), and it trades on the Nasdaq. The company designs, manufactures, and markets robotic-assisted surgical systems and related instruments. Its flagship da Vinci system enables minimally invasive procedures, while the Ion platform targets diagnostic lung biopsies.
The shares carry a market capitalization near $135 billion and a trailing price-to-earnings (P/E) ratio in the mid-40s. In its second quarter of 2026, the company reported revenue of $2.89 billion, up about 19% year over year, with non-GAAP earnings per share (EPS) of $2.80, up roughly 28%. Worldwide procedures — combining da Vinci and Ion — grew approximately 16%.
Despite these strong headline numbers, the stock sold off as investors focused on a slowdown in U.S. da Vinci procedure growth. Management kept full-year procedure guidance at approximately 13.5% to 15.5%, closer to the midpoint, which tempered enthusiasm.
The most durable pillar of the bullish case is the company's recurring-revenue model. Because roughly 85% of sales come from instruments, accessories, and services tied to an installed base of over 11,000 da Vinci systems, revenue visibility is unusually high for a medtech company.
Adoption of the next-generation da Vinci 5 system is another catalyst. The newer platform has demonstrated higher utilization than its predecessor, and hospitals continue placing systems even amid macroeconomic uncertainty. Ion procedures have also grown rapidly, expanding the company's addressable market into lung-cancer screening.
Margins have been a bright spot. Non-GAAP gross margin reached 70% in the latest quarter, and operating margin expanded meaningfully year over year. If procedure growth stabilizes and da Vinci 5 placements continue, earnings growth could support a move toward $500 even without multiple expansion.
Several factors stand in the way. The deceleration in U.S. da Vinci procedure growth is the primary concern, and investors are watching whether that trend reverses. China represents a further headwind, with domestic competition and a lack of clarity on new reimbursement codes weighing on system placements there.
Tariffs on imported components also pressure gross margins, and management has noted uncertainty about how additional duties could affect results. Rising competition from established players such as JNJ (Johnson & Johnson) and MDT (Medtronic) adds a longer-term risk to pricing and market share.
Finally, valuation remains a hurdle. Even after the pullback, Intuitive trades at a substantial premium to the broader medtech industry, leaving limited room for execution missteps.
Sentiment remains broadly positive. The consensus rating is a Buy, with an average 12-month analyst price target near $478 and a range from roughly $324 to $685. Notably, several firms — Oppenheimer, Citi, UBS, and Baird — cluster right at the $500 mark, while Bernstein and Goldman Sachs maintain higher targets. Others, including HSBC and Deutsche Bank, are more cautious, underscoring that the $500 forecast is not unanimous.
From a technical perspective, the 52-week low near $328 represents a critical support level that has held since July 2026. On the upside, the round-number $400 level is likely to act as initial psychological resistance before any sustained advance toward $500. The prior 52-week high near $604 marks the far side of the recent trading range and illustrates the distance the stock has traveled from its peak.
Traders tracking stocks like Intuitive Surgical can also monitor changing conditions through Tickeron's AI Daily Buy/Sell Signals. This tool uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market behavior, technical patterns, and AI-driven analysis. It is designed to help traders identify new opportunities, keep tabs on existing positions, and spot shifting trends more efficiently. For those looking to complement their own research with automated, data-driven alerts, exploring these signals can be a practical next step.
Whether Intuitive Surgical can reach $500 depends less on any single catalyst and more on the trajectory of procedure growth and margin durability. The company's installed base, recurring revenue, and da Vinci 5 upgrade cycle provide a credible foundation for the move, and a $500 target sits squarely within mainstream analyst expectations.
However, the stock's premium valuation, slowing U.S. procedure growth, and China-related uncertainty are meaningful counterweights. Reaching $500 would likely require a stabilization or re-acceleration of procedure volumes, continued system placements, and confirmation that tariff costs are contained. Investors should monitor quarterly procedure data, da Vinci 5 adoption, and any changes to international reimbursement policy as the clearest signals of whether the path to $500 remains open.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ISRG has been closely correlated with BSX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if ISRG jumps, then BSX could also see price increases.
| Ticker / NAME | Correlation To ISRG | 1D Price Change % | ||
|---|---|---|---|---|
| ISRG | 100% | -2.02% | ||
| BSX - ISRG | 73% Closely correlated | -0.46% | ||
| SYK - ISRG | 64% Loosely correlated | -1.98% | ||
| NTRA - ISRG | 54% Loosely correlated | -0.37% | ||
| GKOS - ISRG | 51% Loosely correlated | -1.59% | ||
| PODD - ISRG | 49% Loosely correlated | -0.19% | ||
More | ||||
| Ticker / NAME | Correlation To ISRG | 1D Price Change % |
|---|---|---|
| ISRG | 100% | -2.02% |
| ISRG (2 stocks) | 99% Closely correlated | +2.32% |
| Pharmaceuticals: Other (51 stocks) | 63% Loosely correlated | +1.39% |
| Pharmaceuticals (156 stocks) | 3% Poorly correlated | +1.18% |